About

Ralph Weissleder's Lab

Ralph Weissleder

My laboratory has currently three major areas of interest: 1) An NIH-funded program to develop nanoparticle and other scaffold based libraries to identify novel ligands for interrogation of cellular pathways and to use this information to develop an more comprehensive understanding of in vivo biology; 2) Analyzing the genes and gene products involved in the molecular pathogenesis of complex human diseases (esp. cancer, cardiovascular and diabetes) to identify novel imaging and therapeutic targets; 3) Development of novel miniaturized sensing technologies (chips) for real-time high-throughput analysis of problems in biology.

The lab develops and uses a variety of different tools and platforms for data acquisition. In particular, we aim at obtaining the following information using in vivo systems through bioimaging and parallel sensing:

Recent Publications (more...)

Sosnovik DE, Garanger E, Aikawa E, Nahrendorf M, Figuiredo JL, Dai G, Reynolds F, Rosenzweig A, Weissleder R, Josephson L
Molecular MRI of Cardiomyocyte Apoptosis With Simultaneous Delayed-Enhancement MRI Distinguishes Apoptotic and Necrotic Myocytes In Vivo: Potential for Midmyocardial Salvage in Acute Ischemia.
Circ Cardiovasc Imaging. 2009;2(6):460-467 - PMID: 19920044
Sosnovik DE, Nahrendorf M, Panizzi P, Matsui T, Aikawa E, Dai G, Li L, Reynolds F, Dorn GW, Weissleder R, Josephson L, Rosenzweig A
Molecular MRI Detects Low Levels of Cardiomyocyte Apoptosis in a Transgenic Model of Chronic Heart Failure.
Circ Cardiovasc Imaging. 2009;2(6):468-475 - PMID: 19920045
Smith RA, Yuan H, Weissleder R, Cantley LC, Josephson L
A Wortmannin-Cetuximab as a Double Drug.
Bioconjugate Chem. 2009;20 :2185-2189 - PMID: 19883074

Recent News (more...)

2009-11-09: Nature Nanotechnology Feature article describes CSB work on TB detection using magnetic nanoparticles, microfluidics and nuclear magnetic resonance. (pdf)
2009-10-12: Dr. Ralph Weissleder has been elected as a new member of the U.S. National Academies Institute of Medicine (IOM). This is one of the highest honors in the fields of health and medicine.
2009-08-30: Collaboration between CSB's Dr. Weissleder and MIT's Dr. Cima in developing cancer monitoring methods is described in the New York Times. (pdf)
2009-08-09: CSB's work on TB detection using DMR technology is featured in New Scientist (pdf) and MIT Technology Review (pdf)
2009-08-08: New Boston Museum of Science's Virtual Exhibit features work of Drs. Weissleder and Harisinghani on the design of a clinical trial to determine how iron-oxide nanoparticles could enhance a diagnostic image produced by an MRI machine to the extent that the spread of cancer could be accurately assessed.

Weissleder

Home